Stay updated with breaking news from Advanz. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
The Competition Appeal Tribunal has unanimously upheld the CMA’s decision condemning a pharmaceutical supplier for excessive pricing of medicines sold to the NHS.
Advanz Pharma secures exclusive rights from Alvotech to commercialize five proposed biosimilars in EuropeThe agreement includes proposed biosimilars to Simponi® , Entyvio® and three... | May 24, 2023
Alvotech will be responsible for supply and Advanz will oversee commercialisation of biosimilar - News - PharmaTimes
Advanz Pharma will commercialize AVT23, a proposed biosimilar to Xolair® (omalizumab) in the European Economic Area, UK, Switzerland, Canada, Australia, and New Zealand Alvotech (NASDAQ: ALVO), a global
The deal will give Advanz an increased presence in the treatment of rare diseases - News - PharmaTimes